Abstract
BACKGROUND The osteolytic activity of metastases of prostate cancer was evaluted in relation to total body bone mineral content (TBBMC) and regional bone mineral content (RBMC). METHODS Bone mass was determined by dual-energy X-ray absorptiometry (DXA). Tartrate-resistant acid phosphatase (TRAP) was measured as a biochemical marker of bone resorption. RESULTS In 32 patients (mean age 72 ± 4 years) compared with 32 controls (mean age 73 ± 5 years), there were significant differences in TRAP (P < 0.0001), TBBMC (P < 0.0001), and RBMC in the pelvis (P < 0.0001), legs (P = 0.0001), and trunk (P<0.05), but not in the arms and head (P = ns). In the overall group of subjects, the correlation between TBBMC and TRAP was r = -0.68, P < 0.0001. The correlations remained significant in the patient and control groups separately. CONCLUSIONS The loss of bone mass observed in patients with metastatic prostate cancer was caused mainly by the predominance of bone resorption in the osteoblastic metastases. Prostate 35:243–247, 1998. © 1998 Wiley-Liss, Inc.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
